Scientists Develop Injection That Makes Fat Cells Self-Destruct - Video

Could an injection that destroys fat cells offer a new way to reduce stubborn belly fat and prevent weight regain? An experimental treatment known as CBL-514 has shown promising results in early clinical trials, demonstrating reductions in abdominal fat, including visceral fat surrounding internal organs.

Presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, the findings suggest that CBL-514 could potentially provide a nonsurgical approach to reducing abdominal fat and supporting obesity management.

Unlike conventional weight-loss medications, CBL-514 works by triggering apoptosis, a natural process of programmed cell death, in fat-storing cells called adipocytes.

Researchers analysed data from two phase 2 clinical trials involving participants with body mass index values between 22 and 30 kg/m². The MRI-based analysis included 40 participants at the later follow-up, with 23 receiving CBL-514 and 17 receiving placebo.

Participants received abdominal injections every three weeks for up to 12 weeks, allowing researchers to assess changes in visceral fat volume.

Four weeks after treatment, participants receiving CBL-514 experienced an average 12.01% reduction in visceral fat, compared with a 5.68% increase in the placebo group.

At the later follow-up, visceral fat remained 10.45% below baseline in the treatment group, while the placebo group showed an 11.76% increase.

Earlier phase 2 findings also demonstrated reductions in subcutaneous fat, with 69.6% of treated participants achieving a reduction of at least 150 mL after eight weeks, compared with none receiving placebo.

Animal studies further suggested that combining CBL-514 with tirzepatide could improve weight loss and reduce weight regain after treatment discontinuation. However, these effects remain unconfirmed in humans.

Despite these encouraging findings, researchers emphasised that CBL-514 remains experimental. Larger phase 3 trials are needed to establish its long-term safety, effectiveness and potential benefits for obesity-related metabolic health.

REFERENCE: European Association for the Study of Diabetes. "New injection makes fat cells self-destruct." ScienceDaily. ScienceDaily, 11 October 2026.